Equities research analysts predict that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will report sales of $5.16 million for the current quarter, Zacks reports. Four analysts have provided estimates for BioCryst Pharmaceuticals’ earnings, with the highest sales estimate coming in at $7.84 million and the lowest estimate coming in at $2.91 million. BioCryst Pharmaceuticals reported sales of $7.76 million during the same quarter last year, which indicates a negative year-over-year growth rate of 33.5%. The firm is expected to announce its next quarterly earnings report on Monday, November 6th.
On average, analysts expect that BioCryst Pharmaceuticals will report full year sales of $5.16 million for the current fiscal year, with estimates ranging from $18.36 million to $29.58 million. For the next year, analysts expect that the company will report sales of $24.56 million per share, with estimates ranging from $14.35 million to $34.66 million. Zacks’ sales calculations are an average based on a survey of research firms that follow BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. The firm had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $5.79 million. During the same period last year, the firm earned ($0.22) EPS. The business’s quarterly revenue was down 35.4% on a year-over-year basis.
BCRX has been the subject of several recent analyst reports. ValuEngine downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, September 3rd. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, September 6th. J P Morgan Chase & Co upped their price objective on shares of BioCryst Pharmaceuticals from $4.93 to $9.00 and gave the stock a “neutral” rating in a report on Wednesday, September 6th. Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, June 27th. Finally, BidaskClub raised shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $8.78.
ILLEGAL ACTIVITY WARNING: This story was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://ledgergazette.com/2017/09/20/5-16-million-in-sales-expected-for-biocryst-pharmaceuticals-inc-bcrx-this-quarter.html.
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) opened at 5.43 on Wednesday. The stock’s market cap is $436.72 million. BioCryst Pharmaceuticals has a 1-year low of $3.75 and a 1-year high of $9.25. The company’s 50-day moving average is $4.87 and its 200 day moving average is $6.05.
Large investors have recently added to or reduced their stakes in the stock. UBS Asset Management Americas Inc. acquired a new position in BioCryst Pharmaceuticals during the 1st quarter valued at $392,000. Swiss National Bank raised its stake in BioCryst Pharmaceuticals by 18.7% during the 1st quarter. Swiss National Bank now owns 114,300 shares of the biotechnology company’s stock valued at $960,000 after purchasing an additional 18,000 shares during the last quarter. Bank of New York Mellon Corp raised its stake in BioCryst Pharmaceuticals by 6.8% during the 1st quarter. Bank of New York Mellon Corp now owns 361,289 shares of the biotechnology company’s stock valued at $3,035,000 after purchasing an additional 23,072 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in BioCryst Pharmaceuticals by 23.2% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 333,373 shares of the biotechnology company’s stock valued at $2,801,000 after purchasing an additional 62,792 shares during the last quarter. Finally, Emory University acquired a new position in BioCryst Pharmaceuticals during the 1st quarter valued at $3,153,000. Hedge funds and other institutional investors own 85.80% of the company’s stock.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.